Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Press Releases Year None20212020 Sep 10, 2021 Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19 Sep 01, 2021 Adagio Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference Aug 10, 2021 Adagio Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Aug 05, 2021 Adagio Therapeutics Announces Pricing of Initial Public Offering Jul 29, 2021 Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Director Jul 26, 2021 Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets Jul 19, 2021 Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer May 05, 2021 Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19 Apr 19, 2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 Apr 13, 2021 Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 13
Year None20212020 Sep 10, 2021 Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19 Sep 01, 2021 Adagio Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference Aug 10, 2021 Adagio Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Aug 05, 2021 Adagio Therapeutics Announces Pricing of Initial Public Offering Jul 29, 2021 Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Director Jul 26, 2021 Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets Jul 19, 2021 Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer May 05, 2021 Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19 Apr 19, 2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 Apr 13, 2021 Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 13
Sep 10, 2021 Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
Sep 01, 2021 Adagio Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Aug 10, 2021 Adagio Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jul 29, 2021 Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Director
Jul 26, 2021 Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets
Jul 19, 2021 Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer
May 05, 2021 Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
Apr 19, 2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19
Apr 13, 2021 Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
